
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.
Prof. Salvatore Oliva discusses the latest treatment options for adolescents and adults with EoE and the importance of effective transition of care.
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.

Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.
Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.
Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

Join Dr. Leonard Bacharier as he discusses the definition of clinical remission in pediatric asthma and how it can represent a potential target in pediatric asthma management.

In this ADVENT symposium at the 2024 European Respiratory Society conference, Dr. Sharon Dell highlights the available clinical biologic efficacy data in pediatric severe asthma, suggesting the potential for achieving clinical remission when added to an asthma management plan.
Pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.